Vijaya Diagnostic Centre reported a strong Q1 FY27 with revenue up 22.8% to ₹231 crore. EBITDA grew 34% to ₹98 crore, with margins expanding to 42.7%. The company plans significant expansion with ₹190-195 crore capex.
Vijaya Diagnostic Centre: Strong Q1 FY27 Growth Fueled by Expansion and Margin Gains
Consolidated Revenue: ₹231 crore
Revenue Growth (YoY): 22.8%
Vijaya Diagnostic Centre Ltd. has reported a robust financial performance for the first quarter of FY27, with consolidated revenue reaching ₹231 crore, marking a significant year-on-year increase of 22.8%. This growth was propelled by a 16.5% rise in test volumes, alongside improvements in test mix and pricing.
What just happened
The company posted an EBITDA of ₹98 crore, a 34% jump from the previous year, with EBITDA margins improving by 360 basis points to 42.7%. Profit After Tax (PAT) stood at ₹53 crore, reflecting a 23% margin. Management highlighted that their integrated B2C model, combining radiology and pathology, is driving higher revenue per patient (₹1,860).
Why this matters
This performance underscores the effectiveness of Vijaya Diagnostic's integrated B2C strategy, which allows for greater revenue per patient compared to standalone pathology services. The ability to expand margins while growing volumes and undertaking expansion indicates strong operational execution and pricing power.
The backstory
As of Q1 FY27, Vijaya Diagnostic operates 166 centres, a network comprising 51 hubs and 115 spokes. The company has a strong balance sheet with ₹330 crore in surplus cash, which will fund its aggressive expansion plans.
What changes now
The company has outlined an expansion roadmap over the next 12 months, targeting the commissioning of 9 new hub centres and 10-12 spoke centres. This growth phase will be supported by a capital expenditure of ₹190 crore to ₹195 crore.
Risks to watch
Expansion execution, including site selection and scaling up new centres, remains a key watch point. Additionally, potential future revenue streams from data monetization are currently constrained by regulatory and privacy considerations.
Peer comparison
Management indicated confidence in sustaining over 40% EBITDA margins, partly due to operating leverage from existing clusters. The integrated model's revenue per patient of ₹1,860 was contrasted with pure-play pathology chains, suggesting a competitive advantage.
Context metrics (time-bound)
- Consolidated Revenue (Q1 FY27): ₹231 crore (+22.8% YoY)
- Test Volume Growth (YoY): 16.5%
- EBITDA (Q1 FY27): ₹98 crore (+34% YoY)
- EBITDA Margin: 42.7% (+360 bps YoY)
- Profit After Tax (PAT) (Q1 FY27): ₹53 crore
- Total Centres: 166 (51 hubs, 115 spokes)
- Planned Capex (next 12 months): ₹190-195 crore
- Surplus Cash: ₹330 crore
What to track next
Investors will be watching the execution of the planned expansion of new hub and spoke centres and the continued ability of the company to maintain its high EBITDA margins above 40% amidst this growth phase.